Alnylam Pharma Crashes on Discontinued Late-Stage Trial
Alnylam Pharmaceuticals saw its shares crash on Thursday after the company announced that it will be discontinuing one of its late-stage trials.
All Work
Chris Lange
Coupa Software More Than Doubles in IPO
Coupa Software entered the market sharply higher than anyone had really expected.
Advanced Disposal Services IPO Brings Mixed Reaction
The reaction was somewhat mixed when Advanced Disposal Services entered the market on Thursday.
Aurinia Pharma Skyrockets on Positive Data From Lupus Study
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has been on a meteoric rise over the past month. In this time the stock has gained over 150%, on what has been relatively little news for such a…
Why Scynexis Is Making a Run
Scynexis shares made a handy gain early on Thursday after the company announced the results from a couple of its mid-stage trials.
7 Key FDA Decisions and Clinical Trial Results Coming in Q4
24/7 Wall St. has collected several big FDA decisions and mid- to late-stage trials that should be coming up in November and December.
Yum! Brands Disappoints on Earnings Ahead of China Split
Yum! Brands Inc. (NYSE: YUM) reported third-quarter financial results after the markets closed on Wednesday. The company posted $1.09 in earnings per share (EPS) on $3.32 billion in revenue. There were consensus estimates from…
SEC Settles Misrepresentation Case With Credit Suisse and Executive
The U. S. Securities and Exchange Commission (SEC) recently announced that Credit Suisse Group A.G. (NYSE: CS) has agreed to pay a $90 million penalty and admit wrongdoing to settle charges that it misrepresented…
Immunomedics Falls Sharply on Secondary Offering
Shares of Immunomedics dropped sharply on Wednesday after the company announced the pricing of its secondary offering.
How Analysts View Micron After Earnings
While this earnings report more or less solidified Micron’s position at its current price level, some analysts are still seeing a little more room to run, though one standout that believes this company is…
Eli Lilly Expands Pet Vaccines Portfolio With Boehringer Acquisition
Eli Lilly shares had a bit of a boost on Wednesday after it was announced that one of its subsidiaries would be acquiring Boehringer Ingelheim Vetmedica.
Monsanto Posts Mixed Q4 Results Ahead of Bayer Merger
Monsanto reported mixed fiscal fourth-quarter financial results before the markets opened on Wednesday.
Constellation Brands Wows With Q2 Earnings
Constellation Brands reported better-than-expected fiscal second-quarter financial results before the markets opened on Wednesday.
Micron Shares Initially Rise Despite Q4 Loss
Micron Technology Inc. (NASDAQ: MU) reported its fiscal fourth-quarter financial results after the markets closed on Tuesday. The company posted a net loss of $0.05 per share on $3.22 billion in revenue. There were…
Trinity Biotech Shares in Freefall After Withdrawing FDA Submission
Trinity Biotech PLC (NASDAQ: TRIB) is watching its shares get halved on Tuesday after the company announced that it would withdraw one of its submissions to the U.S. Food and Drug Administration. Specifically, the…
SEC Charges Investment Advisor With Fraud and Cherry-Picking
The SEC has announced fraud charges against an investment adviser accused of "cherry-picking" profitable trades for his own account rather than a client's accounts.
What Analysts Are Saying About the Janus Merger
Janus Capital Group shares saw a handy gain in Monday’s session after it was announced that Janus had agreed to a merger of equals with Henderson Group.
What to Expect From Constellation Brands Earnings
Constellation Brands is expected to report its fiscal second-quarter financial results before the markets open on Wednesday.
What to Look for in Monsanto Earnings
Monsanto is scheduled to release its fiscal fourth-quarter earnings report before the markets open on Wednesday.
Summit Therapeutics Skyrockets on Sarepta Deal
Shares of Summit Therapeutics more than doubled on Tuesday after it was announced that it would be entering into a licensing deal with Sarepta Therapeutics.